Please login to the form below

Not currently logged in
Email:
Password:

Parkinson's

This page shows the latest Parkinson's news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

periods in Parkinson’s disease, as well as Theratechnologies’ Trogarzo (ibalizumab) as an add-on treatment for drug resistant HIV. ... Squibb got the go-ahead for Empliciti (elotuzumab) alongside Celgene’s Pomalyst (pomalidomide) and dexamethasone

Latest news

More from news
Approximately 37 fully matching, plus 219 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as Parkinson’s and Huntington’s disease. ... Examples of ongoing projects include two which target the immune system with an aim to halt nerve cell damage in

  • Genomics integration: can the NHS rise to the challenge? Genomics integration: can the NHS rise to the challenge?

    But it’s about pitching.”. Helen Parkinson (pictured below), head of molecular archival resources at the European Bioinformatics Institute, was also on the panel. ... Genomics has to be collaborative, and that’s what I love about it.

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinsons disease trials

    ‘Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development’. ... Taking all these lessons learned into consideration should markedly lower the risk of a false negative result in clinical trials for disease-modifying

  • Tackling a formidable foe Tackling a formidable foe

    MAVENCLAD’S short-course oral therapy profile is a bonus to a condition freighted with psychological drag-weights. ... But the battle to beat MS continues at pace with the tantalising prospect that wins in the lab could also be translated to treatments

  • Six degrees of participation Six degrees of participation

    For example, a Parkinson’s patient recently told me that although he understood the importance of ‘participating’, he didn’t want to spend any more time than necessary thinking about ... That’s powerful evidence. And it’s right at our

More from intelligence
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest appointments

  • Prevail Therapeutics adds to its board of directors Prevail Therapeutics adds to its board of directors

    The Prevail team has already made great progress in developing potential treatments for Parkinson’s disease and other neurodegenerative diseases, and I look forward to partnering with the team to help

  • Voyager Therapeutics appoints Matthew Ottmer as chief operating officer Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

    He said: “I am thrilled to join Voyager at this important time during the company’s evolution. ... Developing and implementing the initial commercial strategy and planning for VY-AADC for Parkinson’s disease is a top priority, especially as we

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis. ... future. “At the same time we welcome Dennis as a new member of

  • Voyager Therapeutics appoints chief financial officer Voyager Therapeutics appoints chief financial officer

    This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a ... I am thrilled to join the Voyager team and meaningfully contribute

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

More from appointments
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics